IP Library Granted Patent US 9,037,230
Granted Patent B2
US 9,037,230 · App. 11/713,181 · Granted May 19, 2015

Method and device for treating microscopic tumors remaining in tissues following surgical resection

Inventors: Paul Goldfarb (San Diego, CA); Dietmar Rabussay (Solana Beach, CA)
Assignee: OncoSec Medical Incorporated
A61N1/327
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,037,230
App. No.
11/713,181
Granted
May 19, 2015
Kind
B2
Abstract

This invention concerns treating apparently normal tissue surrounding sites of cancerous tumors so as to reduce both the probability of a recurrence of cancer at and near the site of a cancerous tissue, and to reduce the amount of apparently healthy tissue that is usually excised along with the tumor, thereby providing a substantial benefit to the cancer patient by eliminating or delaying tumor recurrence and sparing normal tissue for its functionality and for avoiding unnecessary disfigurement.

Claims (13)

1. A method of reducing recurrence of tumor cell growth in a mammalian tissue, the method comprising:

(a) providing a source for applying an electroporative electric pulse to a tumor and marginal tissue around the tumor;

(b) providing an agent capable of reducing tumor growth to the tumor and marginal tissue around the tumor;

(c) administering said agent to the tumor and marginal tissue around the tumor;

(d) applying the electroporative electric pulse by said source to the tumor and marginal tissue around the tumor, thereby delivering said agent into said cells;

(e) excising the entire tumor, resulting in reducing or eliminating tumor cell growth, wherein excision occurs about 15 minutes after application of the electroporative electric pulse in step (d); and

(f) closing a wound associated with tumor excision,

wherein a second electroporative electric pulse is not applied after steps (e) and (f).

2. The method of claim 1 wherein said agent is selected from the group consisting of Bleomycin, cisplatin, a polypeptide, an antibody, RNAi, an antisense nucleic acid, an expressible gene encoding a therapeutically active polypeptide, a chemokine, and a cytokine.

3. The method of claim 2 wherein said agent is delivered into said mammalian tissue either intravenously or intratumorally.

4. The method of claim 2 wherein said RNAi, anti sense nucleic acid, and expressible gene are formulated in poly-L-glutamate solution.

5. The method of claim 1 wherein said tumor is selected from the group consisting of a cancer cell in cutaneous tissue, a cancer cell located on the head or neck of a mammal, and a melanoma cell.

6. The method of claim 1 wherein said electroporative electric pulse comprises a pulse having a nominal field strength selected from the group consisting of 1500 V/cm, 1200 V/cm, between 800 and 1500 V/cm, between 200 and 800 V/cm.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2024
From: ONCOSEC MEDICAL INCORPORATED
To: GRAND DECADE DEVELOPMENTS LIMITED
Reel/Frame 067000/0484 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2011
From: GENETRONICS, INC.
To: INOVIO PHARMACEUTICALS, INC.
Reel/Frame 026547/0193 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2011
From: INOVIO PHARMACEUTICALS, INC.
To: ONCOSEC MEDICAL INCORPORATED
Reel/Frame 026394/0236 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2007
From: GOLDFARB, PAUL; RABUSSAY, DIETMAR
To: GENETRONICS, INC.
Reel/Frame 019718/0155 →
Continuity (2)
Provisional Application 60778740 · Mar 3, 2006
Related Publication 20070239099A1 · Oct 11, 2007